Total Payments
$28,052
2024 Payments
$6,212
Companies
12
Transactions
58
Medicare Patients
834
Medicare Billing
$144,307
Payment Breakdown by Category
Consulting$19,155 (68.3%)
Research$3,200 (11.4%)
Travel$3,092 (11.0%)
Food & Beverage$1,954 (7.0%)
Other$330.00 (1.2%)
Education$320.60 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,155 | 9 | 68.3% |
| Unspecified | $3,200 | 1 | 11.4% |
| Travel and Lodging | $3,092 | 13 | 11.0% |
| Food and Beverage | $1,954 | 28 | 7.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $330.00 | 1 | 1.2% |
| Education | $320.60 | 6 | 1.1% |
Payments by Type
General
$24,852
57 transactions
Research
$3,200
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $17,507 | 27 | $0 (2024) |
| PFIZER INC. | $3,530 | 2 | $0 (2023) |
| Genentech USA, Inc. | $3,350 | 7 | $0 (2024) |
| Exelixis Inc. | $1,853 | 11 | $0 (2018) |
| Daiichi Sankyo Inc. | $1,290 | 1 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $179.90 | 2 | $0 (2017) |
| Incyte Corporation | $99.95 | 1 | $0 (2017) |
| Janssen Biotech, Inc. | $84.58 | 2 | $0 (2024) |
| Genmab U.S., Inc. | $66.21 | 1 | $0 (2023) |
| AstraZeneca UK Limited | $49.99 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,212 | 16 | AstraZeneca Pharmaceuticals LP ($5,912) |
| 2023 | $11,218 | 14 | AstraZeneca Pharmaceuticals LP ($3,461) |
| 2022 | $2,055 | 1 | AstraZeneca Pharmaceuticals LP ($2,055) |
| 2020 | $11.18 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($11.18) |
| 2019 | $6,422 | 12 | AstraZeneca Pharmaceuticals LP ($6,079) |
| 2018 | $1,853 | 11 | Exelixis Inc. ($1,853) |
| 2017 | $279.85 | 3 | Alexion Pharmaceuticals, Inc. ($179.90) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
| 12/11/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq, Tecentriq Hybreza | Food and Beverage | In-kind items and services | $120.70 | General |
| Category: BioOncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $260.00 | General |
| 09/07/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $49.61 | General |
| Category: Oncology | ||||||
| 07/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 06/21/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 06/03/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Genentech USA, Inc. | Alecensa (Biological) | Food and Beverage | In-kind items and services | $91.37 | General |
| Category: BioOncology | ||||||
| 04/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $67.53 | General |
| 02/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $34.97 | General |
| Category: Oncology | ||||||
| 02/22/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $3.66 | General |
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $80.18 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $52.39 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $49.25 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $45.26 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: Oncology | ||||||
| 12/06/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,290.00 | General |
| 11/01/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| 09/26/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 07/20/2023 | PFIZER INC. | VIZIMPRO (Drug), MEKTOVI, XALKORI | — | In-kind items and services | $3,200.00 | Research |
| Study: DACOMITINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/05/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $66.21 | General |
| Category: Oncology | ||||||
| 06/02/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 02/22/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $2,390.00 | General |
| Category: BioOncology | ||||||
| 02/22/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Travel and Lodging | Cash or cash equivalent | $406.44 | General |
| Category: BioOncology | ||||||
| 02/22/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Travel and Lodging | Cash or cash equivalent | $191.83 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DACOMITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 186 | 386 | $102,083 | $31,001 |
| 2022 | 5 | 203 | 386 | $106,774 | $33,790 |
| 2021 | 5 | 211 | 465 | $124,573 | $42,535 |
| 2020 | 5 | 234 | 450 | $124,883 | $36,981 |
Total Patients
834
Total Services
1,687
Medicare Billing
$144,307
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 144 | $36,534 | $11,002 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 29 | 58 | $21,134 | $6,709 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 52 | $13,122 | $4,068 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $13,197 | $3,683 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 45 | 70 | $12,071 | $3,520 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 37 | $6,025 | $2,017 | 33.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 60 | 179 | $43,509 | $13,707 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 31 | 66 | $23,070 | $7,850 | 34.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 28 | 28 | $14,196 | $4,296 | 30.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 37 | 47 | $7,825 | $2,371 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 29 | $7,069 | $2,261 | 32.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 12 | $6,924 | $1,967 | 28.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 18 | 25 | $4,181 | $1,338 | 32.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 87 | 262 | $61,369 | $21,111 | 34.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 44 | 97 | $32,801 | $11,534 | 35.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 43 | 69 | $11,055 | $3,880 | 35.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 19 | $10,559 | $3,184 | 30.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $8,789 | $2,827 | 32.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 101 | 255 | $57,118 | $16,786 | 29.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 48 | 95 | $30,583 | $8,892 | 29.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 32 | 35 | $18,791 | $5,711 | 30.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 28 | $12,721 | $4,035 | 31.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 26 | 37 | $5,670 | $1,557 | 27.5% |
About Dr. Hirva Mamdani, M.D
Dr. Hirva Mamdani, M.D is a Internal Medicine healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2011. The National Provider Identifier (NPI) number assigned to this provider is 1437446820.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hirva Mamdani, M.D has received a total of $28,052 in payments from pharmaceutical and medical device companies, with $6,212 received in 2024. These payments were reported across 58 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($19,155).
As a Medicare-enrolled provider, Mamdani has provided services to 834 Medicare beneficiaries, totaling 1,687 services with total Medicare billing of $144,307. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Detroit, MI
- Active Since 07/06/2011
- Last Updated 03/17/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1437446820
Products in Payments
- TAGRISSO (Drug) $7,740
- VIZIMPRO (Drug) $3,200
- Tecentriq (Biological) $3,134
- IMFINZI (Biological) $2,190
- IMFINZI (Drug) $941.76
- LORBRENA (Drug) $330.00
- Alecensa (Biological) $212.07
- SOLIRIS (Drug) $179.90
- RYBREVANT (Drug) $84.58
- Epkinly (Drug) $66.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Detroit
Randy Lieberman, Md, MD
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Dr. Philip Philip, Md Phd Frcp, MD PHD FRCP
Internal Medicine — Payments: $708,561
Internal Medicine $708,561
Shirish Gadgeel, Md, MD
Internal Medicine — Payments: $563,542
Internal Medicine $563,542
Pedro Villablanca Spinetto, M.d, M.D
Internal Medicine — Payments: $480,267
Internal Medicine $480,267
Dr. Mir Basir, D.o, D.O
Internal Medicine — Payments: $415,569
Internal Medicine $415,569
Dr. Ammar Sukari, M.d, M.D
Internal Medicine — Payments: $371,746
Internal Medicine $371,746